GSK in $3 billion settlement with the US

Thursday 3 November 2011

GlaxoSmithKline Plc said it has reached an agreement in principle with the US government to pay $3 billion to settle civil and criminal investigations relating to sales and marketing practices, including those for Avandia (rosiglitazone).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom